Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis

ABSTRACT: Take Home Message Surrogate endpoints such as progression-free survival (PFS) and response rate (RR) are used commonly in metastatic urothelial cancer trials. We find that PFS is moderately correlated and RR is poorly correlated with overall survival. When possible, these endpoints should be de-emphasized.

Background

Surrogate endpoints (SEs), such as progression-free survival (PFS) and objective response rate (ORR), are frequently used in clinical trials. The relationship between SEs and overall survival (OS) has not been well described in metastatic urothelial cancer (MUC).

Objective

We evaluated trial-level data to assess the relationship between SEs and OS. We hypothesize a moderate surrogacy relationship between both PFS and ORR with OS.

Design, setting, and part

SUBMITTER: Ghali F 

PROVIDER: S-EPMC9806712 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature